Almirall S.A.
Global biopharmaceutical company specializing in medical dermatology and skin health.
ALM | MC
Overview
Corporate Details
- ISIN(s):
- ES0157097017
- LEI:
- 95980020140005007996
- Country:
- Spain
- Address:
- Ronda General Mitre 151, 08022 Barcelona
- Website:
- http://www.almirall.com
- Sector:
- Manufacturing
Description
Almirall S.A. is a global biopharmaceutical company specializing in medical dermatology. The company focuses on the research, development, manufacturing, and commercialization of proprietary medicines to address significant unmet needs in skin health. Leveraging scientific innovation, Almirall provides medical solutions designed to improve the well-being and quality of life for patients. Its operations encompass in-house research and development, strategic partnerships, and in-licensing to expand its portfolio of dermatological treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-05-12 19:09 |
Almirall realizará una presentación vía webcast para explicar los Resultados de…
|
Spanish | 101.7 KB | ||
| 2024-04-10 17:43 |
Operaciones del contrato de liquidez durante el primer trimestre de 2024
|
Spanish | 184.0 KB | ||
| 2024-04-08 13:45 |
Convocatoria de la Junta General Ordinaria de Accionistas de la Sociedad
|
Spanish | 313.8 KB | ||
| 2024-03-13 08:20 |
La sociedad anuncia acuerdo de licencia con Eloxx Pharmaceuticals
|
Spanish | 96.6 KB | ||
| 2024-02-19 07:03 |
La sociedad anuncia acuerdo de licencia con Novo Nordisk
|
Spanish | 102.7 KB | ||
| 2024-02-19 00:00 |
Corporate Governance Report - Almirall S.A.
|
Spanish | 1022.3 KB | ||
| 2024-02-19 00:00 |
Corporate Governance Report - Almirall S.A.
|
Spanish | 530.8 KB | ||
| 2024-02-19 00:00 | English | 1.5 MB | |||
| 2024-02-19 00:00 | English | 4.6 MB | |||
| 2024-02-19 00:00 | Spanish | 16.7 MB | |||
| 2024-01-04 17:36 |
Operaciones del contrato de liquidez durante el cuarto trimestre de 2023
|
Spanish | 187.3 KB | ||
| 2023-12-12 07:59 |
Almirall y etherna firman una alianza multidiana para desarrollar terapias basa…
|
Spanish | 74.5 KB | ||
| 2023-11-17 11:55 |
EBGLYSS® (lebrikizumab) de Almirall recibe la aprobación de la Comisión Europea…
|
Spanish | 159.8 KB | ||
| 2023-11-09 06:59 |
Almirall remite Presentación de resultados de Nueve meses de 2023
|
Spanish | 2.4 MB | ||
| 2023-10-23 16:44 |
Operaciones del contrato de liquidez durante el tercer trimestre de 2023
|
Spanish | 187.4 KB |
Automate Your Workflow. Get a real-time feed of all Almirall S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Almirall S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Almirall S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
